Genmab

Genmab

Genmab was founded in Copenhagen in 1999 by Jan van de Winkel, who serves as President and CEO, alongside a core team that leveraged antibody expertise developed at Medarex. The company commercialized its foundational DuoBody and HexaBody platforms to generate a pipeline now embedded in multiple FDA-approved therapies. While not a family office, Genmab functions as a capital allocation vehicle directing billions of Danish kroner into oncology and immunology R&D. Genmab deploys capital through a hybrid model combining wholly-owned clinical programs with royalty-bearing out-licensing agreements. Core therapeutic assets cover oncology, immunology, and rare diseases, with a focus on antibody-drug conjugates and bispecific antibodies. Key partnered commercial programs include Darzalex (daratumumab) with Johnson & Johnson for multiple myeloma, and Kesimpta (ofatumumab) with Novartis for multiple sclerosis. The firm's direct investment posture centers on advancing its own pipeline of next-generation antibody candidates while using co-development fees to limit shareholder dilution. The geographic footprint spans R&D sites in Copenhagen and Utrecht, with commercial and clinical operations in Princeton and Tokyo. The firm's market capitalization surpasses 115 billion DKK, with royalty revenues exceeding 13 billion DKK annually, funding a pipeline of over 10 clinical-stage programs. Additional operational hubs include a newly expanded US headquarters in Princeton, New Jersey, and a Japanese subsidiary in Tokyo. In January 2024, Genmab completed its $1.8 billion acquisition of ProfoundBio, gaining a portfolio of next-generation ADC candidates and a clinical-stage ovarian cancer asset (per the firm, January 2024). Genmab's structural differentiator lies in a royalty-funded R&D model that insulates the firm's pipeline from the boom-and-bust capital cycles of smaller biotechs. Where most pre-revenue biotech firms are structurally dependent on secondary offerings, Genmab's Darzalex royalties provide an internal, recurring funding mechanism that allows clinical-stage risk-taking without triggering dilution — a posture more commonly associated with large-cap pharma than a mid-cap European biotech.